SCHEMBL6763705

SCHEMBL6763705

Fc1cc2ccccc2cc1-n1nc(C(F)(F)F)cc1-c1ccco1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.48
ALDH1A1 P00352 6/20 0.48
HPGD P15428 6/20 0.48
HSD17B10 Q99714 6/20 0.48
TSHR P16473 5/20 0.48
TLR8 Q9NR97 1/20 0.42
MAPT P10636 2/20 0.41
PTGS2 P35354 1/20 0.41
PTGS1 P23219 1/20 0.41
GAA P10253 1/20 0.41
POLB P06746 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
ATM Q13315 1/20 0.40
F10 P00742 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5399982 0.85 KDM4E (0.44) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL5377696 0.84 KDM4E (0.43) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL950629 0.81 RXRA (0.52) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL950143 0.80 PTGS1 (0.64) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL27518390 0.80 KDM4E (0.40) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL7230019 0.78 KDM4E (0.44) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL7230519 0.78 KDM4E (0.44) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL25897540 0.78 KDM4E (0.44) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL29766643 0.78 KDM4E (0.44) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL23358701 0.78 PTGS1 (0.53) KDM4EALDH1A1HPGDHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040116399-A1 Inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2004-06-17 US disclosed
US-6632815-B2 Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades MILLENNIUM PHARMACEUTICALS, INC. 2003-10-14 US disclosed
US-20020091116-A1 Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades MILLENNIUM PHARMACEUTICALS, INC. 2002-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091116-A1 Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades SERPINC1, TFPI, F2 KDM4E 3940/4885ALDH1A1 4324/4885HPGD 1241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.